Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

Omacetaxine Mepesuccinate for Chronic Myeloid Leukemia.

Expert review of hematology - 1 May 2016

Rosshandler Yasmin, Shen Ann Q, Cortes Jorge, Khoury Hanna Jean

Abstract excerpt

Omacetaxine mepesuccinate is approved by the Food and Drug Administration in the United States for the treatment of chronic myeloid leukemia in chronic or accelerated phase resistant to two or more tyrosine kinase inhibitors. This review summarizes the mode of action, pharmacokinetics, efficacy and safety of omacetaxine mepesuccinate. Omacetaxine mepesuccinate has activity in chronic myeloid leukemia, especially...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Angiogenesis Inhibitors
Share to Antineoplastic Agents, Phytogenic
Share to Blast Crisis

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Share to Fusion Proteins, bcr-abl

Share to Leukemia, Myelogenous, Chronic, BCR-ABL Positive

Share to Mutation

Share to Treatment Outcome

Source

Identifiers

PMID: 26853281
DOI: 10.1586/17474086.2016.1151351

Genes

ABL1

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 3 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

Omacetaxine Mepesuccinate for Chronic Myeloid Leukemia.PMID 26853281Read ↗

Phase 2 study of subcutaneous omacetaxine mepesuccinate after TKI failure in patients with chronic-phase CML with T315I mutation.Semantic proximity Read ↗

Chronic Myeloid Leukemia, Version 1.2019, NCCN Clinical Practice Guidelines in OncologySemantic proximity Read ↗

Chronic myeloid leukemia: 2020 update on diagnosis, therapy and monitoringSemantic proximity Read ↗

Treatment of chronic myelogenous leukemia.Semantic proximity Read ↗

State-of-the-art in the treatment of chronic myeloid leukaemia.Semantic proximity Read ↗

Asciminib in the treatment of chronic myeloid leukemia in chronic phase.Semantic proximity Read ↗

Asciminib in chronic myeloid leukemia.Semantic proximity Read ↗

Asciminib in Chronic Myeloid Leukemia after ABL Kinase Inhibitor Failure.Semantic proximity Read ↗

Homoharringtonine, omacetaxine mepesuccinate, and chronic myeloid leukemia circa 2009Semantic proximity Read ↗

The Durable Clearance of the T315I BCR-ABL Mutated Clone in Chronic Phase Chronic Myelogenous Leukemia Patients on Omacetaxine Allows Tyrosine Kinase Inhibitor RechallengeSemantic proximity Read ↗

Asciminib for chronic myeloid leukaemia: Next questions.Semantic proximity Read ↗

Asciminib (Scemblix): A third-line treatment option for chronic myeloid leukemia in chronic phase with or without T315I mutation.Semantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.